Rhythm Pharmaceuticals, Inc.
RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) dā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$104.60
Price-1.04%
-$1.10
1Y
Price
Market Cap
$6.981b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-93.1%
EBITDA Margin-103.1%
Net Profit Margin-51.9%
Free Cash Flow MarginRevenue
$174.334m
+34.0%
1y CAGR+109.9%
3y CAGR+244.8%
5y CAGREarnings
-$192.326m
+26.2%
1y CAGR-5.6%
3y CAGR-44.3%
5y CAGREPS
-$3.10
+28.6%
1y CAGR+0.6%
3y CAGR-38.6%
5y CAGRBook Value
$148.817m
$506.874m
Assets$358.057m
Liabilities$151.005m
DebtDebt to Assets
29.8%
-0.9x
Debt to EBITDAFree Cash Flow
-$109.131m
+4.2%
1y CAGR+14.6%
3y CAGR+6.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company